Will percutaneous valves replace the surgical valves: Another one bites the dust?
Trans-cutaneous valve implantation (TAVI) has witnessed rapid evolution in terms of technical design, efficacy, and safety outcomes. This has led to expanding indications of TAVI from inoperable to high surgical to now even lower surgical risk patients. However, its cost and applicability only in elderly patients with degenerated valves is a cause of concern limiting the use of this technology. Further evolution may lead to its application in lower risk essentially younger patients with broader etiologic sub-groups.
Professor of Cardiology, AIIMS, New Delhi, India. Electronic address: sundeepmishraihj@gmail.com.
Sundeep
S
Mishra
D000368:Aged; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006801:Humans; D011474:Prosthesis Design; D065467:Transcatheter Aortic Valve Replacement / Q000379:methods*
Aortic stenosis; CoreValve(®); Cost effectiveness; Elderly; Percutaneous valve; Prosthetic valve degeneration; Prosthetic valve function; SAVR; Sapien XT(®); TAVI; TAVR